PDF(Pubmed)
Abstract：
Patients with liver cirrhosis, due to their weakened innate and adaptive immunity, are more prone to frequent and severe vaccine-preventable infections. Moreover, impaired adaptive immunity results in a limited antibody response to vaccines. Despite this suboptimal antibody response, vaccines have proven to be very effective in reducing severe outcomes and deaths in these patients. In the Western world, regulatory authorities and scientific liver societies (e.g., AASLD and EASL) have recommended vaccinations for cirrhotic patients. However, despite these strong recommendations, vaccine coverage remains suboptimal. Improving vaccine effectiveness and safety information, providing comprehensive counseling to patients, fact-checking to combat fake news and disinformation and removing barriers to vaccination for disadvantaged individuals may help overcome the low coverage rate. In view of this, vaccines should be administered early in the course of chronic liver diseases, as their efficacy declines with the increasing severity of the disease.
摘要：
肝硬化患者，由于先天和适应性免疫力减弱，更容易发生频繁和严重的疫苗可预防的感染。此外，受损的适应性免疫导致对疫苗的有限抗体应答。尽管抗体反应欠佳,疫苗已被证明在减少这些患者的严重结局和死亡方面非常有效.在西方世界,监管机构和科学肝脏协会(例如，AASLD和EASL）建议对肝硬化患者接种疫苗。然而,尽管有这些强有力的建议，疫苗覆盖率仍然不够理想。提高疫苗有效性和安全性信息，为患者提供全面的咨询，事实核查以打击假新闻和虚假信息，消除弱势群体接种疫苗的障碍，可能有助于克服低覆盖率。鉴于此,疫苗应在慢性肝病的早期接种，因为它们的功效随着疾病严重程度的增加而下降。
